JP7150343B2 - チアゾール誘導体およびその使用 - Google Patents

チアゾール誘導体およびその使用 Download PDF

Info

Publication number
JP7150343B2
JP7150343B2 JP2019557668A JP2019557668A JP7150343B2 JP 7150343 B2 JP7150343 B2 JP 7150343B2 JP 2019557668 A JP2019557668 A JP 2019557668A JP 2019557668 A JP2019557668 A JP 2019557668A JP 7150343 B2 JP7150343 B2 JP 7150343B2
Authority
JP
Japan
Prior art keywords
compound
group
synthesis
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019557668A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504184A (ja
JP2020504184A5 (enExample
Inventor
海鷹 賀
志▲ガン▼ 江
衛華 石
建華 夏
健 黎
曙輝 陳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaeno Therapeutics Co Ltd
Original Assignee
Phaeno Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phaeno Therapeutics Co Ltd filed Critical Phaeno Therapeutics Co Ltd
Publication of JP2020504184A publication Critical patent/JP2020504184A/ja
Publication of JP2020504184A5 publication Critical patent/JP2020504184A5/ja
Application granted granted Critical
Publication of JP7150343B2 publication Critical patent/JP7150343B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019557668A 2017-01-09 2018-01-09 チアゾール誘導体およびその使用 Active JP7150343B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710014893 2017-01-09
CN201710014893.9 2017-01-09
PCT/CN2018/071964 WO2018127207A1 (zh) 2017-01-09 2018-01-09 噻唑衍生物及其应用

Publications (3)

Publication Number Publication Date
JP2020504184A JP2020504184A (ja) 2020-02-06
JP2020504184A5 JP2020504184A5 (enExample) 2021-02-04
JP7150343B2 true JP7150343B2 (ja) 2022-10-11

Family

ID=62789152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557668A Active JP7150343B2 (ja) 2017-01-09 2018-01-09 チアゾール誘導体およびその使用

Country Status (5)

Country Link
US (1) US10647710B2 (enExample)
EP (1) EP3566749A4 (enExample)
JP (1) JP7150343B2 (enExample)
CN (1) CN110225781B (enExample)
WO (1) WO2018127207A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR113344A1 (es) 2017-10-05 2020-04-22 Innovative Molecules Gmbh Enantiómeros de una serie de compuestos antivirales
KR102535452B1 (ko) * 2018-07-06 2023-05-26 파에노 테라퓨틱스 씨오., 엘티디. 티아졸 화합물의 결정형 및 이의 응용
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
WO2025082442A1 (zh) * 2023-10-17 2025-04-24 辉诺生物医药科技（杭州）有限公司 (r)-5-卤素-2,3-二氢-1h-茚-2-羧酸的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519134A (ja) 1999-12-23 2003-06-17 バイエル アクチェンゲゼルシャフト チアゾリルアミド誘導体
JP2008530042A (ja) 2005-02-11 2008-08-07 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ２アンタゴニストとしてのピラゾロピリミジン誘導体
WO2015197763A1 (en) 2014-06-26 2015-12-30 Deutsches Krebsforschungszentrum Topical application for an anti-hsv antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455104T1 (de) * 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
DE10210319A1 (de) * 2002-03-08 2003-09-18 Bayer Ag Thiazolylcarbonyl-Derivate
DE10226048A1 (de) * 2002-06-12 2003-12-24 Bayer Ag Thiazolylsulfonamide
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519134A (ja) 1999-12-23 2003-06-17 バイエル アクチェンゲゼルシャフト チアゾリルアミド誘導体
JP2008530042A (ja) 2005-02-11 2008-08-07 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ２アンタゴニストとしてのピラゾロピリミジン誘導体
WO2015197763A1 (en) 2014-06-26 2015-12-30 Deutsches Krebsforschungszentrum Topical application for an anti-hsv antibody

Also Published As

Publication number Publication date
WO2018127207A1 (zh) 2018-07-12
EP3566749A4 (en) 2020-09-23
CN110225781B (zh) 2022-05-17
CN110225781A (zh) 2019-09-10
US10647710B2 (en) 2020-05-12
JP2020504184A (ja) 2020-02-06
EP3566749A1 (en) 2019-11-13
US20190375744A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
JP6754505B2 (ja) Ａｓｋ１阻害剤、その調製方法および使用
CN105837576B (zh) Btk抑制剂
ES2902050T3 (es) Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1
JP7150343B2 (ja) チアゾール誘導体およびその使用
JP7123956B2 (ja) スピロ化合物およびその使用
RU2669701C2 (ru) Производные пиперидина в качестве антагонистов рецептора орексина
CN104860931A (zh) 丙肝病毒抑制剂及其制药用途
NZ572201A (en) Inhibitors of c-fms kinase
CA3054324C (en) Tri-cycle compound and applications thereof
CN104974161B (zh) 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
JP6118470B2 (ja) 抗ウイルス剤として使用されるイミダゾール誘導体及び該イミダゾール誘導体の薬剤の製造における使用
TW201620913A (zh) 作為PARP抑制劑的4H-吡唑並[1,5-α]苯並咪唑化合物的類似物
CN110845502A (zh) 一种7-溴吡咯并[2,1-f][1,2,4]噻嗪-4-胺的制备方法
WO2018192493A1 (zh) 作为pcsk9抑制剂的哌啶类化合物
KR102547709B1 (ko) 아제티딘 유도체
KR0130467B1 (ko) 아자비시클로알칸류
JP7050054B2 (ja) Ｐｄｅ４阻害剤としての縮合環系化合物
JP7245832B2 (ja) ピリミジンスルファミド系誘導体、その製造方法およびその医薬における使用
TWI784074B (zh) 用於製備苯并噻吩-2-基硼酸酯之方法
KR102481328B1 (ko) S1p1 작용제 및 이의 응용
CN114605404B (zh) 一种新型含噻唑类化合物、中间体及其应用
CN111303120A (zh) 一种盐酸法舒地尔的制备方法
CN106661009A (zh) 抗肠病毒71噻二唑烷衍生物
JP2025521507A (ja) 置換縮合二環式化合物および関連する治療方法
WO2018086531A1 (zh) 作为cccDNA抑制剂的磺酰胺类化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201216

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220920

R150 Certificate of patent or registration of utility model

Ref document number: 7150343

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250